The First Affiliated Hospital of Soochow University: Multiple Myeloma trials

The registry lists 20 Multiple Myeloma studies with The First Affiliated Hospital of Soochow University as lead sponsor. 11 are open to participants now and 0 have results posted.

Early Phase 1 2Phase 1 5Phase 2 3Phase 3 1Phase 4 3No phase 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study on the Use of Sulpegfilgrastim to Prevent the Incidence of Neutropenia With Infection in Newly Diagnosed Non-transplant Multiple Myeloma PatientsNot yet recruitingNCT07018271Not applicable
• The Efficacy and Safety of the Combination Therapy of Daratumumab, Cabozantinib, Pomalidomide, and Dexamethasone (D-KPd) in the Treatment of High-risk First-time Relapsed or Primary Refractory MM PatientsNot yet recruitingNCT07015021Not applicable
• A Clinical Trial Evaluating the Safety Tolerability, Radiation Absorption Dose, Distribution, PET Imaging and Histological Expression of 68Ga-NOTA-SCH001 in Patients With Multiple MyelomaNot yet recruitingNCT06925958Not applicable
• A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell LeukemiaRecruitingNCT06730256Early Phase 1
• Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) PatientsRecruitingNCT06682156
• Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease DetectionRecruitingNCT06409702Phase 4
• Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma PatientsRecruitingNCT05855122Phase 4
• CT0594CP CAR-T Cells in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell LeukemiaRecruitingNCT05822037Not applicable
• Efficacy and Safety of Daratumumab in Combination With Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple MyelomaNot yet recruitingNCT05561049
• Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma PatientsRecruitingNCT04025450Phase 1/2
• Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple MyelomaRecruitingNCT03196414Phase 1/2
• Cohort Construction and Prognostic Model Construction for Multiple MyelomaActive, not recruitingNCT06366802
• An Open Label, Single-arm Clinical Study Evaluating the Safety and Efficacy of ICI201 Infusion in Relapsed/Refractory Multiple MyelomaWithdrawnNCT05980507Phase 1
• This is an Open-label, Single Arm Study to Evaluate the Safety and Tolerability of Treatment With CT0591CP in Patients With Relapsed and/or Refractory Multiple Myeloma.Status unknownNCT05486975Early Phase 1
• Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y001#CompletedNCT05270928Phase 1
• A Study to Access of Daratumumab Combined With VRD in the Treatment of Patients With Standard-risk Newly Diagnosed MMStatus unknownNCT05088330Not applicable
• A Study to Access the Safety and Efficacy of CT0590 in Patients With Relapsed and/or Refractory Multiple MyelomaStatus unknownNCT05066022Not applicable
• Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) PatientsStatus unknownNCT04287660Phase 3
• PDD vs PAD to Treat Initially Diagnosed MMStatus unknownNCT02577783Phase 4
• Study of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma in ChinaStatus unknownNCT01812096Phase 1/2